Monday, December 17, 2007 7:09:23 AM
Monday December 17, 6:00 am ET
Five of 20 Evaluable Patients Had Confirmed Partial Responses (25%); Updated Data Presented at San Antonio Breast Cancer Symposium
HAYWARD, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN - News) today announced that its Hsp90 inhibitor, tanespimycin, demonstrated meaningful antitumor activity and tolerability in a Phase 2 trial in patients with HER2-positive metastatic breast cancer, when administered in combination with trastuzumab (Herceptin®) in patients whose disease progressed following treatment with trastuzumab immediately prior to entering the trial. Of 20 evaluable patients, 11 patients benefited from activity, yielding an overall clinical benefit incidence of 55%, including 5 patients with confirmed partial responses, 2 patients with minor responses and 4 patients with extended stable disease. Common toxicities were mainly mild to moderate and included fatigue and gastrointestinal symptoms. Data from the Phase 2 trial were presented at the 2007 San Antonio Breast Cancer Symposium on Sunday, December 16, 2007, in a poster titled, "Tanespimycin (an Hsp90 Inhibitor) and Trastuzumab is an Active Combination in Patients (Pts) with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer (MBC): Phase 2 Trial," by Shanu Modi, M.D., of Memorial Sloan-Kettering Cancer Center.
http://biz.yahoo.com/prnews/071217/aqm014a.html?.v=4
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM